CASP3 and breast cancer: Additionally, we found that the cleavage of caspase-3 and PARP-1 were also improved in varying degrees by 3-MA in breast cancer cells treated by the BEZ235 and TSA combination group, indicating that dual drug treatment may trigger apoptosis and autophagy, leading to cell death of breast cancer cells via a caspase-dependent pathway.